Warfarin Pharmacogenetics: does more accurate dosing benefit patients?

Por Eby, Charles
Publicado no Semin Thromb Hemost (2012)

Safety concerns related to use of unapproved needles for accessing implantable venous access devices

Por Powers, Michelle L. E., Lublin, Douglas, Eby, Charles, Leitman, Susan F., Dynis, Marian, Despotis, George J.
Publicado em 2009

Interactive Modeling for Ongoing Utility of Pharmacogenetic Diagnostic Testing: Application for Warfarin Therapy

Por Linder, Mark W., Homme, Marjorie Bon, Reynolds, Kristen K., Gage, Brian F., Eby, Charles, Silvestrov, Natalia, Valdes, Roland
Publicado em 2009

Gamma-glutamyl carboxylase and its influence on warfarin dose

Por King, Cristi R., Deych, Elena, Milligan, Paul, Eby, Charles, Lenzini, Petra, Grice, Gloria, Porche-Sorbet, Rhonda M., Ridker, Paul M., Gage, Brian F.
Publicado em 2010

A Randomized Phase II Trial Investigating the Effect of Platelet Function Inhibition on Circulating Tumor Cells in Patients With Metastatic Breast Cancer

Por Roop, Ryan P., Naughton, Michael J., Van Poznak, Catherine, Schneider, Jochen G., Lammers, Philip E., Pluard, Timothy J., Johnson, Farley, Eby, Charles S., Weilbaecher, Katherine N.
Publicado em 2013

Ability of VKORC1 and CYP2C9 to Predict Therapeutic Warfarin Dose During the Initial Weeks of Therapy

Por Ferder, Nicholas, Eby, Charles S., Deych, Elena, Harris, Jenine K., Ridker, Paul M., Milligan, Paul, Goldhaber, Samuel Z., King, Cristi R., Giri, Tusar, McLeod, Howard L., Glynn, Robert J., Gage, Brian F.
Publicado em 2009

Genetic-based dosing in orthopedic patients beginning warfarin therapy

Por Millican, Eric A., Lenzini, Petra A., Milligan, Paul E., Grosso, Leonard, Eby, Charles, Deych, Elena, Grice, Gloria, Clohisy, John C., Barrack, Robert L., Burnett, R. Stephen J., Voora, Deepak, Gatchel, Susan, Tiemeier, Amy, Gage, Brian F.
Publicado em 2007

Genetics InFormatics Trial (GIFT) of Warfarin to Prevent Deep Vein Thrombosis (DVT): Rationale and Study Design

Por Do, Elizabeth J., Lenzini, Petra, Eby, Charles S., Bass, Anne R., McMillin, Gwendolyn A., Stevens, Scott M., Woller, Scott C., Pendleton, Robert C., Anderson, Jeffrey L., Proctor, Pam, Nunley, Ryan M., Davila-Roman, Victor, Gage, Brian F.
Publicado em 2011

Laboratory and Clinical Outcomes of Pharmacogenetic vs. Clinical Protocols for Warfarin Initiation in Orthopedic Patients

Por Lenzini, Petra A., Grice, Gloria R., Milligan, Paul E., Dowd, Mary Beth, Subherwal, Sumeet, Deych, Elena, Eby, Charles S., King, Cristi R., Porche-Sorbet, Rhonda M., Murphy, Claire V., Marchand, Renee, Millican, Eric A., Barrack, Robert L., Clohisy, John C., Kronquist, Kathryn, Gatchel, Susan K., Gage, Brian F.
Publicado em 2008

CYP4F2 genetic variant alters required warfarin dose

Por Caldwell, Michael D., Awad, Tarif, Johnson, Julie A., Gage, Brian F., Falkowski, Mat, Gardina, Paul, Hubbard, Jason, Turpaz, Yaron, Langaee, Taimour Y., Eby, Charles, King, Cristi R., Brower, Amy, Schmelzer, John R., Glurich, Ingrid, Vidaillet, Humberto J., Yale, Steven H., Qi Zhang, Kai, Berg, Richard L., Burmester, James K.
Publicado em 2008

Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trial

Por Kimmel, Stephen E., French, Benjamin, Anderson, Jeffrey L., Gage, Brian F., Johnson, Julie A., Rosenberg, Yves D., Geller, Nancy L., Kasner, Scott E., Eby, Charles S., Joo, Jungnam, Caldwell, Michael D., Goldhaber, Samuel Z., Hart, Robert G., Cifelli, Denise, Madigan, Rosemary, Brensinger, Colleen M., Goldberg, Suzanne, Califf, Robert M., Ellenberg, Jonas H.
Publicado no Am Heart J (2013)

Venous Thromboembolic Disease: Clinical Practice Guidelines in Oncology

Por Streiff, Michael B., Bockenstedt, Paula L., Cataland, Spero R., Chesney, Carolyn, Eby, Charles, Fanikos, John, Fogarty, Patrick F., Gao, Shuwei, Garcia-Aguilar, Julio, Goldhaber, Samuel Z., Hassoun, Hani, Hendrie, Paul, Holmstrom, Bjorn, Jones, Kimberly A., Kuderer, Nicole, Lee, Jason T., Millenson, Michael M., Neff, Anne T., Ortel, Thomas L., Smith, Judy L., Yee, Gary C., Zakarija, Anaadriana
Publicado em 2011

Pharmacogenetic Warfarin Dose Refinements Remain Significantly Influenced by Genetic Factors after One Week of Therapy

Por Horne, Benjamin D., Lenzini, Petra A., Wadelius, Mia, Jorgensen, Andrea L., Kimmel, Stephen E., Ridker, Paul M., Eriksson, Niclas, Anderson, Jeffrey L., Pirmohamed, Munir, Limdi, Nita A., Pendleton, Robert C., McMillin, Gwendolyn A., Burmester, James K., Kurnik, Daniel, Stein, C. Michael, Caldwell, Michael D., Eby, Charles S., Rane, Anders, Lindh, Jonatan D., Shin, Jae-Gook, Kim, Ho-Sook, Angchaisuksiri, Pantep, Glynn, Robert J., Kronquist, Kathryn E., Carlquist, John F., Grice, Gloria R., Barrack, Robert L., Li, Juan, Gage, Brian F.
Publicado em 2011

A Pharmacogenetic versus a Clinical Algorithm for Warfarin Dosing

Por Kimmel, Stephen E., French, Benjamin, Kasner, Scott E., Johnson, Julie A., Anderson, Jeffrey L., Gage, Brian F., Rosenberg, Yves D., Eby, Charles S., Madigan, Rosemary A., McBane, Robert B., Abdel-Rahman, Sherif Z., Stevens, Scott M., Yale, Steven, Mohler, Emile R., Fang, Margaret C., Shah, Vinay, Horenstein, Richard B., Limdi, Nita A., Muldowney, James A.S., Gujral, Jaspal, Delafontaine, Patrice, Desnick, Robert J., Ortel, Thomas L., Billett, Henny H., Pendleton, Robert C., Geller, Nancy L., Halperin, Jonathan L., Goldhaber, Samuel Z., Caldwell, Michael D., Califf, Robert M., Ellenberg, Jonas H.
Publicado em 2013